Bacterin International Holdings, Inc. (BONE) - Medical Equipment - Deals and Alliances Profile

Bacterin International Holdings, Inc. (BONE) - Medical Equipment - Deals and Alliances Profile

Bone Metabolism Therapeutics Market

Bone Market

Summary

Bacterin International Holdings, Inc. (Bacterin) is a medical device company and accredited tissue bank that designs, processes, manufactures, and markets advanced medical products. The company operates in two divisions, namely, Biologics Division and Coatings Division. Biologics Division offers OsteoSponge product line and an allograft portfolio designed specifically to meet the needs of the Spine, Cranio-maxillofacial, reconstructive, and trauma markets. The company's product portfolio include OsteoSponge, OsteoWrap, OsteoSelect, OsteoLock, BacFast, Sports Medicine, Traditional allografts and Coated Devices (Antimicrobial-Coated Wound Drains).The company's Coatings Division develops medical devices intended for use in several diverse clinical areas including orthopedic, plastic, and cardiovascular surgery. The company has an FDA and ISO 13485:2003 registered facility in Belgrade. The company's Biologics Division operates out of a 16,000 square foot facility with a processing laboratory that consists of five Class 100 clean rooms. The Biologics Division follows Good Tissue Practice (cGTP) and Good Manufacturing Practice (cGMP). Bacterin is headquartered in Belgrade, Montana, The US.

Bacterin International Holdings, Inc. (BONE) - Medical Equipment - Deals and Alliances Profile provides you an in-depth data and trend analysis of the companys mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalDatas proprietary in-house Medical Equipment eTrack deals database and primary and secondary research.

Scope

Financial Deals - Analysis of the companys financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Business Description - A brief description of the companys operations.
Key Employees A list of the key executives of the company.
Important Locations and Subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key Competitors A list of key competitors of the company.
Key Recent Developments A brief on recent news about the company.


Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements.
- The profile analyzes the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divesture strategy
- Deals are presented from the companys core business segments perspective to help you understand its corporate strategy

Access detailed information about the companys recent financial deals that enables you to understand the key deals which have shaped the company
- Major recent deals are presented in detail, which provides information on each deals brief summary, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company
- Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.
- Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

» Read More...

Bacterin International Holdings, Inc. (BONE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bacterin International Holdings, Inc. (BONE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bone Metabolism Therapeutics Market

Bone Market

Summary

Bacterin International Holdings, Inc. (Bacterin) is a medical device company and accredited tissue bank that designs, processes, manufactures, and markets advanced medical products. The company operates in two divisions, namely, Biologics Division and Coatings Division. Biologics Division offers OsteoSponge product line and an allograft portfolio designed specifically to meet the needs of the Spine, Cranio-maxillofacial, reconstructive, and trauma markets. The company's product portfolio include OsteoSponge, OsteoWrap, OsteoSelect, OsteoLock, BacFast, Sports Medicine, Traditional allografts and Coated Devices (Antimicrobial-Coated Wound Drains).The company's Coatings Division develops medical devices intended for use in several diverse clinical areas including orthopedic, plastic, and cardiovascular surgery. The company has an FDA and ISO 13485:2003 registered facility in Belgrade. The company's Biologics Division operates out of a 16,000 square foot facility with a processing laboratory that consists of five Class 100 clean rooms. The Biologics Division follows Good Tissue Practice (cGTP) and Good Manufacturing Practice (cGMP). Bacterin is headquartered in Belgrade, Montana, The US.

Bacterin International Holdings, Inc. (BONE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

 

» Read More...

Small Bone Innovations, Inc. - Medical Equipment - Deals and Alliances Profile

Small Bone Innovations, Inc. - Medical Equipment - Deals and Alliances Profile

 

Bone Metabolism Therapeutics Market

Bone Market

Summary

Small Bone Innovations, Inc. (SBI) designs and manufactures orthopedics implants. The company is engaged in the research and development of ultramodern implants and devices in orthopedics. It develops, markets and distributes upper and lower extremity products that are used in bone trauma surgery and large joint surgery. Its arthroplasty and trauma products are used in the treatment of trauma and diseases in small bones and joints. The companys product portfolio includes orthopedic implants, spacers, metacarpophalangeal implants, proximal interphalangeal implants, fusion plates, soft skeletal implants, IM nail systems, total wrist systems, dorsal distal radius plates, BBR wires, proximal radial head prosthesis and external fixation systems. The company markets its products in North America, South America, Asia, the Middle East, Africa, Europe, French Polynesia, Australia and New Zealand. SBI is headquartered in New York, the US.

Small Bone Innovations, Inc. - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical Equipment eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

 

List of Table:

List of Tables
Small Bone Innovations, Inc., Medical Equipment, Key Facts 1
Small Bone Innovations, Inc., Medical Equipment, Deals By Year, 2006 to YTD 2012 1
Small Bone Innovations, Inc., Medical Equipment, Deals By Region, 2006 to YTD 2012 1
Small Bone Innovations, Inc., Medical Equipment, Deals By Market, 2006 to YTD 2012 1
Small Bone Innovations, Inc., Medical Equipment, Deals Summary, 2006 to YTD 2012 1
Small Bone Innovations, Inc., Medical Equipment, Deals By Year, 2006 to YTD 2012 5
Small Bone Innovations, Inc., Medical Equipment Deals By Type, 2006 to YTD 2012 6
Small Bone Innovations, Inc., Medical Equipment, Deals By Region, 2006 to YTD 2012 7
Small Bone Innovations, Inc., Deals By Market, 2006 to YTD 2012 8
Small Bone Innovations, Inc., Medical Equipment, Deals Summary, 2006 to YTD 2012 9
Small Bone Innovations Acquires The Scandinavian Total Ankle Replacement System From Deru And Waldemar Link 11
Small Bone Innovations Acquires Assets From Euromedic International 13
Small Bone Innovations Acquires Intellectual Property For Reverse Great Toe Prosthesis From Shane M. Hollawell 14
Small Bone Innovations Acquires Intellectual Property For Trihedron Great Toe Hemi Implant From Charles Sorbie And Gerald Saunders 15
Small Bone Innovations Secures $4.3 Million In Financing Round 16
Small Bone Innovations Secures $15 Million In Series F Financing Round 17
Small Bone Innovations Secures $12 Million In Financing Round 19
Small Bone Innovations Secures $108 Million In Series D Financing 20
Small Bone Innovations Secures $36 Million In Series C Preferred Stock Financing 22
Artimplant Amends Its Licensing Agreement With Small Bone Innovations 24
Artimplant Signs An Agreement With Small Bone Innovations 25
Small Bone Innovations Enters Into An Agreement With Therics 26
Small Bone Innovations Enters Into An Agreement With litos 27
Small Bone Innovations Enters Into A Licensing Agreement With S. Robert 28
Small Bone Innovations Enters Into Distribution Agreement With Biomet Nederland 29
Olympus Terumo Biomaterials Enters Into Distribution Agreement With Small Bone Innovations 30
Small Bone Innovations Sells Shoulder-Related Assets To Fx Solutions 31
Small Bone Innovations Receives Investment Of $12 Million From OLYMPUS 32
Small Bone Innovations Acquires Link Orthopaedics 33
Small Bone Innovations, Inc., Key Competitors 34
Small Bone Innovations, Inc., Key Employees 35
Small Bone Innovations, Inc., Other Locations 36
Small Bone Innovations, Inc., Subsidiaries 36

List of Charts:

List of Figures
Small Bone Innovations, Inc., Medical Equipment, Deals by Type, 2006 to YTD 2012 1
Small Bone Innovations, Inc., Medical Equipment, Deals By Year, 2006 to YTD 2012 5
Small Bone Innovations, Inc., Medical Equipment, Deals by Type, 2006 to YTD 2012 6
Small Bone Innovations, Inc., Medical Equipment, Deals By Region, 2006 to YTD 2012 7
Small Bone Innovations, Inc., Medical Equipment, Deals by Market, 2006 to YTD 2012 8

 

 

Small Bone Innovations, Inc. - Medical Equipment - Deals and Alliances Profile

 

Bone Metabolism Therapeutics Market

Bone Market

 

 

» Read More...

Rathbone Brothers Plc (RAT) - Financial and Strategic SWOT Analysis Review

Rathbone Brothers Plc (RAT) - Financial and Strategic SWOT Analysis Review

Bone Metabolism Therapeutics Market

Bone Market

Rathbone Brothers Plc (Rathbone) is a provider of independent investment and wealth management services to private client and trustees. The company, along with its five subsidiaries, provides investment management services and related professional advisory services to private individuals, trustees, charities, pension funds, and the professional advisers. Rathbone offers a wide range of financial services such as discretionary investment management, unit trusts, tax planning, trust and company management, pension advice, and private banking services. It also provides investment services, and advisory stock broking services; and taxation services. Rathbone operates its business through three segments namely, investment management, unit trust, and trust and tax services segment. It has its operations in the UK and Jersey. Rathbone is headquartered in London, the UK.

This comprehensive SWOT profile of Rathbone Brothers Plc provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalDatas Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, GlobalDatas highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Rathbone Brothers Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

 

Table of Contents

Section 1 - About the Company

Rathbone Brothers Plc - Key Information
Rathbone Brothers Plc - Overview
Rathbone Brothers Plc - Key Employees
Rathbone Brothers Plc - Key Employee Biographies
Rathbone Brothers Plc - Key Operational Heads
Rathbone Brothers Plc - Major Products and Services
Rathbone Brothers Plc - History
Rathbone Brothers Plc - Company Statement
Rathbone Brothers Plc - Locations And Subsidiaries

Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis

Rathbone Brothers Plc - Business Description
Rathbone Brothers Plc - Corporate Strategy
Rathbone Brothers Plc - SWOT Analysis
SWOT Analysis - Overview
Rathbone Brothers Plc - Strengths
Rathbone Brothers Plc - Weaknesses
Rathbone Brothers Plc - Opportunities
Rathbone Brothers Plc - Threats
Rathbone Brothers Plc - Key Competitors

Section 3 - Company Financial Performance Charts

Rathbone Brothers Plc - Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer


Note*: Some sections may be missing if data is unavailable for the company

List of Table:

List of Tables

Rathbone Brothers Plc, Key Information
Rathbone Brothers Plc, Key Ratios
Rathbone Brothers Plc, Share Data
Rathbone Brothers Plc, Major Products and Services
Rathbone Brothers Plc, History
Rathbone Brothers Plc, Key Employees
Rathbone Brothers Plc, Key Employee Biographies
Rathbone Brothers Plc, Key Operational Heads
Rathbone Brothers Plc, Other Locations
Rathbone Brothers Plc, Subsidiaries

Rathbone Brothers Plc, Key Competitors
Rathbone Brothers Plc, SWOT Analysis
Rathbone Brothers Plc, Ratios based on current share price
Rathbone Brothers Plc, Annual Ratios
Rathbone Brothers Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Charts:

List of Figures

Rathbone Brothers Plc, Performance Chart
Rathbone Brothers Plc, Ratio Charts

Rathbone Brothers Plc (RAT) - Financial and Strategic SWOT Analysis Review

Bone Metabolism Therapeutics Market

Bone Market

 

 

» Read More...

Bonefish Grill: Foodservice Company Profile & SWOT Report

Bonefish Grill: Foodservice Company Profile & SWOT Report

Bone Metabolism Therapeutics Market

Bone Market

Product Synopsis
Canadean's "Bonefish Grill: Foodservice Company Profile & SWOT Report" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.

Introduction and Landscape
Canadean's "Bonefish Grill: Foodservice Company Profile & SWOT Report" is a crucial resource for industry executives and anyone looking to access key information about "Bonefish Grill"

Canadean's "Bonefish Grill: Foodservice Company Profile & SWOT Report" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Canadean strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Key Features and Benefits
Examines and identifies key information and issues about "Bonefish Grill" for business intelligence requirements.
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
The profile also contains information on business operations, company history, major products and services, prospects, key employees, locations and subsidiaries.


Key Market Issues
Quickly enhance your understanding of "Bonefish Grill"
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
Increase business/sales activities by understanding your competitors businesses better.
Recognize potential partnerships and suppliers.

Key Highlights
Bonefish Grill Inc. (Bonefish Grill) is a seafood restaurant group based in the US. The company was established in 2000 at St. Petersburg in Florida, the US. The company's menu comprises a range of fish and related products such as grilled fish, grilled specialties, saut

 

1 Business Analysis
1.1 Company Overview
1.2 Business Description
1.3 Major Products and Services
2 Recent Developments
3 SWOT Analysis
3.1 SWOT Analysis - Overview
3.2 Strengths
3.3 Weaknesses
3.4 Opportunities
3.5 Threats
4 History
5 Key Employees
6 Key Employee Biographies
7 Locations and Subsidiaries
7.1 Head Office
7.2 Other Locations and Subsidiaries
8 Appendix
8.1 Methodology
8.2 Disclaimer

List of Table:

Table 1: Major Products and Services
Table 2: History
Table 3: Key Employees
Table 4: Key Employee Biographies
Table 5: Locations

 

Bonefish Grill: Foodservice Company Profile & SWOT Report

Bone Metabolism Therapeutics Market

Bone Market

 

 

» Read More...

Bone Cancer Pipeline Review, H1 2012

Bone Cancer Pipeline Review, H1 2012

Bone Metabolism Therapeutics Market

Bone Market

Summary

Global Markets Directs, 'Bone Cancer - Pipeline Review, H1 2012', provides an overview of the Bone Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. 'Bone Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Bone Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bone Cancer Therapeutic Products under Development, Key Players in Bone Cancer Therapeutics, Bone Cancer Pipeline Overview, Bone Cancer Pipeline, Bone Cancer Pipeline Assessment

 

Table of Contents
Table of Contents 2
List of Tables 17
List of Figures 18
Introduction 19
Global Markets Direct Report Coverage 19
Bone Cancer Overview 20
Therapeutics Development 21
An Overview of Pipeline Products for Bone Cancer 21
Bone Cancer Therapeutics under Development by Companies 23
Bone Cancer Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 31
Comparative Analysis 31
Mid Clinical Stage Products 32
Comparative Analysis 32
Early Clinical Stage Products 33
Comparative Analysis 33
Discovery and Pre-Clinical Stage Products 34
Comparative Analysis 34
Bone Cancer Therapeutics Products under Development by Companies 35
Bone Cancer Therapeutics Products under Investigation by Universities/Institutes 36
Companies Involved in Bone Cancer Therapeutics Development 43
Genzyme Corporation 43
Amgen Inc. 44
Eli Lilly and Company 45
Merck & Co., Inc. 46
Infinity Pharmaceuticals, Inc. 47
ZIOPHARM Oncology, Inc. 48
ImClone Systems Incorporated 49
Cephalon, Inc. 50
Genta Incorporated 51
Bayer AG 52
Advaxis, Inc. 53
Oncolytics Biotech Inc. 54
Osteologix, Inc. 55
Green Cross Corporation 56
Algeta ASA 57
Simcere Pharmaceutical Group 58
Merrion Pharmaceuticals Plc 59
Digna Biotech, S.L. 60
Debiopharm Group 61
Amura Holdings Ltd. 62
Hawthorn Pharmaceuticals, Inc. 63
Deciphera Pharmaceuticals, LLC 64
Jennerex Biotherapeutics, Inc. 65
Virobay Inc. 66
PharmaMar, S.A. 67
Targa Therapeutics Corp. 68
Epeius Biotechnologies Corporation 69
Bone Cancer Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Route of Administration 72
Assessment by Molecule Type 74
Drug Profiles 77
Xgeva - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
IMC-A12 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
G4544 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Ridaforolimus - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ART010 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
IPI-926 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Debio 0719 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Ganitumab - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
AYRPVSRNI + IFA + Interferon Alpha - Drug Profile 194
Product Description 194
Mechanism of Action 194
R&D Progress 194
Mozobil - Drug Profile 195
Product Description 195
Mechanism of Action 195
R&D Progress 195
High Dose Methotrexate - Drug Profile 197
Product Description 197
Mechanism of Action 197
R&D Progress 197
Zoledronic acid + Gleevec - Drug Profile 198
Product Description 198
Mechanism of Action 198
R&D Progress 198
Temsirolimus + Valproic Acid - Drug Profile 199
Product Description 199
Mechanism of Action 199
R&D Progress 199
CEP-37251 - Drug Profile 200
Product Description 200
Mechanism of Action 200
R&D Progress 200
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 201
Product Description 201
Mechanism of Action 201
R&D Progress 201
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile 203
Product Description 203
Mechanism of Action 203
R&D Progress 203
Afinitor - Drug Profile 237
Product Description 237
Mechanism of Action 237
R&D Progress 237
haw mAb11 - Drug Profile 238
Product Description 238
Mechanism of Action 238
R&D Progress 238
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 239
Product Description 239
Mechanism of Action 239
R&D Progress 239
RO4929097 + Dexamethasone - Drug Profile 240
Product Description 240
Mechanism of Action 240
R&D Progress 240
Zymafos + Etoposide + Carboplatin - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
AM-3701 - Drug Profile 242
Product Description 242
Mechanism of Action 242
R&D Progress 242
Leuprolide + Doxorubicin Hydrochloride + Zoledronate - Drug Profile 243
Product Description 243
Mechanism of Action 243
R&D Progress 244
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile 245
Product Description 245
Mechanism of Action 245
R&D Progress 245
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile 247
Product Description 247
Mechanism of Action 247
R&D Progress 248
Cytoxan + Doxorubicin + Vincristine + Irinotecan + Temozolomide + Neulasta + Mesnex - Drug Profile 249
Product Description 249
Mechanism of Action 249
R&D Progress 250
Etoposide + Carboplatin + Cyclophosphamide + Mesna + Melphalan + Tandem Peripheral Blood Stem Cell - Drug Profile 251
Product Description 251
Mechanism of Action 251
R&D Progress 252
Vincristine + Cyclophosphamide + Adriamycin + Etoposide + Cisplatin + Carboplatin + Melphalan + Ifosfamide + Granulocyte-Colony Stimulating Factor + Mesna - Drug Profile 253
Product Description 253
Mechanism of Action 253
R&D Progress 253
VEGF/rGel - Drug Profile 255
Product Description 255
Mechanism of Action 255
R&D Progress 255
Vincristine + Topotecan + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide - Drug Profile 257
Product Description 257
Mechanism of Action 257
R&D Progress 258
Vincristine + Doxorubicin + Cyclophosphamide + Dexrazoxane + ImmTher + Mesna + Neupogen + Neulasta - Drug Profile 259
Product Description 259
Mechanism of Action 259
R&D Progress 260
EF-2 Peptide + IL-2 + Autologous T-Cell Transplantation - Drug Profile 261
Product Description 261
Mechanism of Action 261
R&D Progress 261
EF-2 Peptide + IL-2 - Drug Profile 263
Product Description 263
Mechanism of Action 263
R&D Progress 263
PXFK Peptide + IL-2 - Drug Profile 264
Product Description 264
Mechanism of Action 264
R&D Progress 264
PXFK Peptide + IL-2 + Autologous T cell Transplantation - Drug Profile 265
Product Description 265
Mechanism of Action 265
R&D Progress 266
E7 Peptide + IL-2 - Drug Profile 267
Product Description 267
Mechanism of Action 267
R&D Progress 267
E7 Peptide + IL-2 + Autologous T Cell Transplantation - Drug Profile 269
Product Description 269
Mechanism of Action 269
R&D Progress 269
Thalidomide - Drug Profile 271
Product Description 271
Mechanism of Action 271
R&D Progress 271
Hydroxychloroquine + Radiation Therapy - Drug Profile 272
Product Description 272
Mechanism of Action 272
R&D Progress 272
Docetaxel + Carboplatin + Trastuzumab + Bevacizumab - Drug Profile 273
Product Description 273
Mechanism of Action 273
R&D Progress 273
Docetaxel + Rhenium-186 HEDP - Drug Profile 275
Product Description 275
Mechanism of Action 275
R&D Progress 275
MG1102 - Drug Profile 276
Product Description 276
Mechanism of Action 276
R&D Progress 276
DCC-2909 - Drug Profile 277
Product Description 277
Mechanism of Action 277
R&D Progress 277
Bone Cancer Therapeutics Drug Profile Updates 278
Bone Cancer Therapeutics Discontinued Products 302
Bone Cancer Therapeutics - Dormant Products 304
Bone Cancer Product Development Milestones 313
Featured News & Press Releases 313
Apr 26, 2012: Amgen Receives Complete Response Letter From FDA For XGEVA sBLA For Prevention Of Bone Metastases 313
Apr 17, 2012: Daiichi Sankyo Launches RANMARK In Japan 313
Mar 31, 2012: Researchers State Combination Of Two Targeted Therapies Act Against Ewing's Sarcoma Tumors 314
Mar 29, 2012: NICE Recommends Use Of Amgen's Denosumab For Certain Groups Of Cancer Patients 315
Mar 20, 2012: Merck And ARIAD Provide Update On FDA Advisory Committee Vote On Ridaforolimus For Treatment Of Sarcomas 316
Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711 316
Feb 10, 2012: Analysis Of Updated ALSYMPCA Phase III Data Confirms Overall Survival Benefit Of Alpharadin In Castration-Resistant Prostate Cancer Patients With Bone Metastases 317
Feb 02, 2012: Algeta Announces Initiation Of Expanded Access Program For Alpharadin In US 317
Feb 01, 2012: Detailed Results From ALSYMPCA Phase III Study Highlight Positive Impact Of Alpharadin On Skeletal-related Events Associated With Bone Metastases From Castration-Resistant Prostate Cancer 317
Jan 27, 2012: Algeta Announces Results From ALSYMPCA Phase III Study With Alpharadin To Be Presented At 2012 Genitourinary Cancers Symposium 319
Appendix 320
Methodology 320
Coverage 320
Secondary Research 320
Primary Research 320
Expert Panel Validation 320
Contact Us 321
Disclaimer 321

List of Table:

List of Tables
Number of Products Under Development for Bone Cancer, H1 2012 21
Products under Development for Bone Cancer Comparative Analysis, H1 2012 22
Number of Products under Development by Companies, H1 2012 24
Number of Products under Development by Companies, H1 2012 (Contd..1) 25
Number of Products under Investigation by Universities/Institutes, H1 2012 27
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 28
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 29
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 30
Comparative Analysis by Late Stage Development, H1 2012 31
Comparative Analysis by Mid Clinical Stage Development, H1 2012 32
Comparative Analysis by Early Clinical Stage Development, H1 2012 33
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 34
Products under Development by Companies, H1 2012 35
Products under Investigation by Universities/Institutes, H1 2012 36
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 37
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 38
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 39
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 40
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 41
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 42
Genzyme Corporation, H1 2012 43
Amgen Inc., H1 2012 44
Eli Lilly and Company, H1 2012 45
Merck & Co., Inc., H1 2012 46
Infinity Pharmaceuticals, Inc., H1 2012 47
ZIOPHARM Oncology, Inc., H1 2012 48
ImClone Systems Incorporated, H1 2012 49
Cephalon, Inc., H1 2012 50
Genta Incorporated, H1 2012 51
Bayer AG, H1 2012 52
Advaxis, Inc., H1 2012 53
Oncolytics Biotech Inc., H1 2012 54
Osteologix, Inc., H1 2012 55
Green Cross Corporation, H1 2012 56
Algeta ASA, H1 2012 57
Simcere Pharmaceutical Group, H1 2012 58
Merrion Pharmaceuticals Plc, H1 2012 59
Digna Biotech, S.L., H1 2012 60
Debiopharm Group, H1 2012 61
Amura Holdings Ltd., H1 2012 62
Hawthorn Pharmaceuticals, Inc., H1 2012 63
Deciphera Pharmaceuticals, LLC, H1 2012 64
Jennerex Biotherapeutics, Inc., H1 2012 65
Virobay Inc., H1 2012 66
PharmaMar, S.A., H1 2012 67
Targa Therapeutics Corp., H1 2012 68
Epeius Biotechnologies Corporation, H1 2012 69
Assessment by Monotherapy Products, H1 2012 70
Assessment by Combination Products, H1 2012 71
Assessment by Stage and Route of Administration, H1 2012 73
Assessment by Stage and Molecule Type, H1 2012 76
Bone Cancer Therapeutics Drug Profile Updates 278
Bone Cancer Therapeutics Discontinued Products 302
Bone Cancer Therapeutics Discontinued Products (Contd..1) 303
Bone Cancer Therapeutics Dormant Products 304
Bone Cancer Therapeutics Dormant Products (Contd..1) 305
Bone Cancer Therapeutics Dormant Products (Contd..2) 306
Bone Cancer Therapeutics Dormant Products (Contd..3) 307
Bone Cancer Therapeutics Dormant Products (Contd..4) 308
Bone Cancer Therapeutics Dormant Products (Contd..5) 309
Bone Cancer Therapeutics Dormant Products (Contd..6) 310
Bone Cancer Therapeutics Dormant Products (Contd..7) 311
Bone Cancer Therapeutics Dormant Products (Contd..8) 312

List of Charts:

List of Figures
Number of Products under Development for Bone Cancer, H1 2012 21
Products under Development for Bone Cancer Comparative Analysis, H1 2012 22
Products under Development by Companies, H1 2012 23
Products under Investigation by Universities/Institutes, H1 2012 26
Late Stage Products, H1 2012 31
Mid Clinical Stage Products, H1 2012 32
Early Clinical Stage Products, H1 2012 33
Discovery and Pre-Clinical Stage Products, H1 2012 34
Assessment by Monotherapy Products, H1 2012 70
Assessment by Combination Products, H1 2012 71
Assessment by Route of Administration, H1 2012 72
Assessment by Stage and Route of Administration, H1 2012 73
Assessment by Molecule Type, H1 2012 74
Assessment by Stage and Molecule Type, H1 2012 75

Bone Cancer Pipeline Review, H1 2012

Bone Metabolism Therapeutics Market

Bone Market

 

 

 

» Read More...

Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

Bone Metabolism Therapeutics Market to 2018 – Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

Bone Metabolism Therapeutics Market

Bone Market

GBI Research, the leading business intelligence provider, has released its latest research, Bone Metabolism Therapeutics Market to 2018 Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar, which provides insights into bone metabolic disease therapeutics until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report provides an in-depth analysis of the major bone metabolic diseases, including osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases. The report also provides the share of generics in global bone metabolic diseases as well as in each indication market. It also provides the treatment algorithm flow for each of the four indications. The report examines the global bone metabolic diseases treatment usage patterns. In addition, the geographical distribution of bone metabolic diseases and markets across the US, the top five countries of Europe, and in Japan, are provided in the report. The report also includes insights into the bone metabolic diseases R&D product pipeline and explores the competitive landscape, including major players in the bone metabolism therapeutics market. Finally, the report also includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the bone metabolism therapeutics market.

GBI Researchs analysis shows that the overall global bone metabolism therapeutics market for the four indications (which includes osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases) was valued at $15 billion in 2010, growing from $10.1 billion in 2002 and indicating a CAGR of 5.2%. GBI Research forecasts the market to grow at a CAGR of 7.7% between 2010 and 2018 to record a sales value of $27.1 billion by 2018. The growth in the bone metabolism therapeutics market is mainly due to the contribution of osteoporosis market. The revenue of osteoporosis market alone has approximately 68% of the total bone metabolism revenue. So, the global bone metabolism market is growing inspite of the declining market nature of the rest of therapeutics areas discussed here.

Scope

  • Data and analysis on the metabolic disorder therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the metabolic disorder therapeutics market from 2002 to 2010, with forecasts to 2018 for the three indications osteoporosis, Pagets disease of bone, hyperparathyroidism and bone metastases.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in the global bone metabolism therapeutics market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global bone metabolism therapeutics market, including top companies benchmarking. The key companies studied in this report are Amgen Inc., Abbott Laboratories, Genzyme Corporation, Merck & Co. Inc. and Novartis AG.
  • Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorders therapeutics market.

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 11

3 Bone Metabolism Therapeutics Market to 2018 – Market Overview 12
3.1 Introduction 12
3.1.1 Revenue 12
3.1.2 Annual Cost of Treatment 13
3.1.3 Treatment Usage Patterns 14

4 Bone Metabolism Therapeutics Market to 2018 – Geographical Landscape 16
4.1 Revenue Analysis by Geography 16
4.2 The US 18
4.2.1 Revenue 18
4.2.2 Annual Cost of Treatment 19
4.2.3 Treatment Usage Patterns 20
4.3 Top Five Countries of Europe 22
4.3.1 Revenue 22
4.3.2 Annual Cost of Treatment 24
4.3.3 Treatment Usage Patterns 25
4.4 Japan 27
4.4.1 Revenue 27
4.4.2 Annual Cost of Treatment 28
4.4.3 Treatment Usage Patterns 29

5 Bone Metabolism Therapeutics Market to 2018 – Therapeutic Landscape 31
5.1 Osteoporosis Therapeutics Market 31
5.1.1 Introduction 31
5.1.2 Revenue 31
5.1.3 Annual Cost of Treatment 35
5.1.4 Treatment Usage Patterns 36
5.1.5 Treatment Flow Algorithm 38
5.1.6 Drivers and Barriers for the Osteoporosis Therapeutics Market 39
5.2 Pagets Disease of Bone Therapeutics Market 40
5.2.1 Introduction 40
5.2.2 Revenue 40
5.2.3 Annual Cost of Treatment 45
5.2.4 Treatment Usage Patterns 46
5.2.5 Treatment Flow Algorithm 48
5.2.6 Drivers and Barriers for the Pagets Disease of Bone Therapeutics Market 49
5.3 Hyperparathyroidism Therapeutics Market 50
5.3.1 Introduction 50
5.3.2 Revenue 50
5.3.3 Annual Cost of Treatment 55
5.3.4 Treatment Usage Patterns 56
5.3.5 Treatment Flow Algorithm 58
5.3.6 Drivers and Barriers for the Hyperparathyroidism Therapeutics Market 59
5.4 Bone Metastases Therapeutics Market 60
5.4.1 Introduction 60
5.4.2 Revenue 60
5.4.3 Annual Cost of Treatment 65
5.4.4 Treatment Usage Patterns 66
5.4.5 Treatment Flow Algorithm 68
5.4.6 Drivers and Barriers for the Bone Metastases Therapeutics Market 68

6 Bone Metabolism Therapeutics Market to 2018 – Pipeline Analysis 70
6.1 Introduction 70
6.2 Bone Metabolism Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 72
6.2.1 Filed Molecules 72
6.2.2 Phase III 73
6.2.3 Phase II 78
6.2.4 Phase I 80
6.2.5 Preclinical Phase 81
6.2.6 Discovery Phase 82
6.3 Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market 82
6.3.1 Alpharadin (radium-223 chloride) 82
6.3.2 Orazol (Zoledronic acid) 83
6.3.3 Xgeva (denosumab) 83
6.3.4 Boniva (ibandronate sodium hydrate) 84
6.3.5 Odanacatib (odanacatib) 85
6.3.6 GTH-42V 85
6.3.7 Viviant (bazedoxifene) 86

7 Bone Metabolism Therapeutics Market to 2018 – Competitive Profiling 87
7.1 Competitive Profiling 87
7.1.1 Amgen Inc. 87
7.1.2 Abbott Laboratories 89
7.1.3 Genzyme Corporation 90
7.1.4 Merck & Co., Inc. 91
7.1.5 Novartis AG 93

8 Bone Metabolism Therapeutics Market to 2018 – Strategic Consolidations 95
8.1 Mergers and Acquisitions 95
8.1.1 Segmentation by Deal Value 97
8.1.2 Segmentation by Geography 99
8.2 Co-development Deals 100
8.2.1 Summary of Co-development Deals 101
8.3 Licensing Deals 102
8.3.1 Summary of Licensing Deals 103

9 Bone Metabolism Therapeutics Market to 2018 – Appendix 105
9.1 Market Definitions 105
9.2 Abbreviations 105
9.3 Sources 106
9.4 Research Methodology 106
9.4.1 Coverage 106
9.4.2 Secondary Research 107
9.4.3 Primary Research 107
9.5 Therapeutic Landscape 108
9.5.1 Epidemiology-based Forecasting 108
9.5.2 Market Size by Geography 110
9.6 Geographical Landscape 111
9.7 Pipeline Analysis 111
9.8 Competitive Landscape 111
9.8.1 Expert Panel Validation 111
9.9 Contact Us 111
9.10 Disclaimer 112

List of Table:

Table 1: Bone Metabolism Therapeutics Market, Global, Revenue ($bn), 2002-2010

Table 2: Bone Metabolism Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018

Table 3: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010

Table 4: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018

Table 5: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010

Table 6: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018

Table 7: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010

Table 8: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018

Table 9: Bone Metabolism Therapeutics Market, The US, Revenue ($bn), 2002-2010

Table 10: Bone Metabolism Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2018

Table 11: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010

Table 12: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2018

Table 13: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2010

Table 14: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018

Table 15: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010

Table 16: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2018

Table 17: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue ($bn), 2002-2010

Table 18: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue Forecasts ($bn), 2010-2018

Table 19: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010

Table 20: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2018

Table 21: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2010

Table 22: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010-2018

Table 23: Bone Metabolism Therapeutics Market, Japan, Revenue ($bn), 2002-2010

Table 24: Bone Metabolism Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2018

Table 25: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010

Table 26: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018

Table 27: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010

Table 28: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018

Table 29: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2002-2010

Table 30: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2018

Table 31: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010

Table 32: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2018

Table 33: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010

Table 34: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018

Table 35: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010

Table 36: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018

Table 37: Paget’s Disease of Bone Therapeutics Market, Global, Revenue ($m), 2002-2010

Table 38: Paget’s Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018

Table 39: Paget’s Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010

Table 40: Paget’s Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018

Table 41: Paget’s Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010

Table 42: Paget’s Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018

Table 43: Paget’s Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010

Table 44: Paget’s Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018

Table 45: Hyperparathyroidism Therapeutics Market, Global, Revenue ($m), 2002-2010

Table 46: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018

Table 47: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010

Table 48: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018

Table 49: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010

Table 50: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018

Table 51: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010

Table 52: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2018

Table 53: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2002-2010

Table 54: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2018

Table 55: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010

Table 56: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2018

Table 57: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010

Table 58: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2018

Table 59: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010

Table 60: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2018

Table 61: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, NDA-filed Molecules

Table 62: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase III Molecules

Table 63: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase II Molecules

Table 64: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Phase I Molecules

Table 65: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase Molecules

Table 66: Bone Metabolism Therapeutics Market, Global, Pipeline Analysis, Discovery Phase Molecules

Table 67: Bone Metabolism Therapeutics Market, Global, M&A, 2009-2011

Table 68: Bone Metabolism Therapeutics Market, M&A Deals, by Value ($m) 2009-2011

Table 69: Bone Metabolism Therapeutics Market, Co-development, by Geography, 2009-2011

Table 70: Bone Metabolism Therapeutics Market, Licensing Deals, by Geography, 2009-2011

List of Charts:
Figure 1: Bone Metabolism Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2018 12
Figure 2: Bone Metabolism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 13
Figure 3: Bone Metabolism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 14
Figure 4: Bone Metabolism Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2018 16
Figure 5: Bone Metabolism Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2018 18
Figure 6: Bone Metabolism Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2018 19
Figure 7: Bone Metabolism Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2018 20
Figure 8: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2018 22
Figure 9: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, by Geography, Revenue Forecasts ($bn), 2002-2018 23
Figure 10: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2018 24
Figure 11: Bone Metabolism Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002-2018 25
Figure 12: Bone Metabolism Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2018 27
Figure 13: Bone Metabolism Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2018 28
Figure 14: Bone Metabolism Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2018 29
Figure 15: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2018 31
Figure 16: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2018 32
Figure 17: Osteoporosis Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 34
Figure 18: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 35
Figure 19: Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 36
Figure 20: Osteoporosis Therapeutics Market, Treatment Flow Algorithm 38
Figure 21: Osteoporosis, Market Drivers and Barriers 39
Figure 22: Pagets Disease of Bone Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 41
Figure 23: Pagets Disease of Bone Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 42
Figure 24: Pagets Disease of Bone Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 44
Figure 25: Pagets Disease of Bone Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 45
Figure 26: Pagets Disease of Bone Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 46
Figure 27: Pagets Disease of Bone Therapeutics Market, Treatment Flow Algorithm 48
Figure 28: Pagets Disease of Bone, Market Drivers and Barriers 49
Figure 29: Hyperparathyroidism Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 50
Figure 30: Hyperparathyroidism Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 52
Figure 31: Hyperparathyroidism Therapeutics Market, Global, Branded vs. Generic Share, 2010 and 2018 54
Figure 32: Hyperparathyroidism Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 55
Figure 33: Hyperparathyroidism Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2018 56
Figure 34: Hyperparathyroidism Therapeutics Market, Treatment Flow Algorithm 58
Figure 35: Hyperparathyroidism, Market Drivers and Barriers 59
Figure 36: Bone Metastases Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2018 61
Figure 37: Bone Metastases Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2018 62
Figure 38: Bone Metastases Therapeutics Market, Global, Branded vs. Generic Share, 2002 and 2018 64
Figure 39: Bone Metastases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2018 65
Figure 40: Bone Metastases Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2018 66
Figure 41: Bone Metastases Therapeutics Market, Treatment Flow Algorithm 68
Figure 42: Bone Metastases, Market Drivers and Barriers 69
Figure 43: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 70
Figure 44: Bone Metabolism Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 71
Figure 45: Bone Metabolism Therapeutics Market, Global, SWOT – Amgen Inc., 2010 88
Figure 46: Bone Metabolism Therapeutics Market, Global, SWOT – Abbott Laboratories, 2010 89
Figure 47: Bone Metabolism Therapeutics Market, Global, SWOT – Genzyme Corporation, 2010 90
Figure 48: Bone Metabolism Therapeutics Market, Global, SWOT – Merck & Co., Inc., 2010 92
Figure 49: Bone Metabolism Therapeutics Market, Global, SWOT – Novartis AG, 2010 94
Figure 50: Bone Metabolism Therapeutics Market, Global, Deals by Indication, 2009-2011 95
Figure 51: Bone Metabolism Therapeutics Market, M&A Deals, by Value ($m) 2009-2011 97
Figure 52: Bone Metabolism Therapeutics Market, M&A Deals, by Geography ($m) 2009-2011 99
Figure 53: Bone Metabolism Therapeutics Market, Licensing Deals, by Geography, 2009-2011 103
Figure 54: GBI Research Market Forecasting Model 110

Bone Metabolism Therapeutics Market to 2018 – Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar

Bone Metabolism Therapeutics Market

Bone Market

 

 

 

» Read More...

Search This Blog

About Me

My photo

The dedicated team of researchers and analysts at Business Research Industry into the Advantage of Knowledge for your company. Data becomes knowledge through the application of Dolcera's optimization process as follows.

Archives

Business Research Industry. Powered by Blogger.